



CERTIFICATE OF MAILING

THEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED APR 2 4 2001

WITH THE UNITED STATES POSTAL SERVICE AS FIRST-CLASS MAILTH AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS ENTER 1600/2900

WASHINGTON, D.C. 20231, ON APRIL 17, 2001

GENT/ATTORNEY FOR APPLICANT

Docket No. 1134C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Duvick, et al.

Date:

April 17, 2001

Serial No.:

09/771.045

Group Art Unit:

1633

Filed

January 26, 2001

Examiner:

For:

"Amino Polyol Amine Oxidase Polynucleotides and Related Polypeptides and

Methods of Use"

Assistant Commissioner for Patents Washington, D.C. 20231

TRANSMITTAL

Transmitted herewith are the following documents: Response to Notice to Comply; Substitute computer readable form (CFR) copy of the Sequence Listing; Substitute paper copy of Sequence Listing; and Statement to Support Filing and Submission in Accordance with 37 CFR §§1.821 through 1.825.

Although there should be no fees associated with the filing of these documents the Commissioner is hereby authorized to charge any processing fees associated with said documents, or to credit any overpayment, to Deposit Account 16-1852. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Ki_nh_R

Karen Moon Bruce Agent for Applicant(s)

Registration No. 42,366

PIONEER HI-BRED INTERNATIONAL, INC.

Corporate Intellectual Property 7100 N.W. 62nd Avenue P.O. Box 1000

Johnston, Iowa 50131-1000

Phone: (515) 248-4879 Facsimile: (515) 334-6883





RECEIVED I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED TO THE PROPERTY OF A SOCIAL PROP WITH THE UNITED STATES POSTAL SERVICE AS FIRST-CLASS MALL IN ALL ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PAFFINES WASHINGTON, D.C. 20231, ON APRIL 17, 2001 WITH THE UNITED STATES POSTAL SERVICE AS FIRST-CLASS MAIL IN AN

AGENT/ATTORNEY FOR APPLICANT 7,2001

Docket No. 1134C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Duvick, et al.

Date:

April 17, 2001

Serial No.:

09/771,045

Group Art Unit:

1633

Filed

January 26, 2001

Examiner:

For:

"Amino Polyol Amine Oxidase Polynucleotides and Related Polypeptides and

Methods of Use"

Assistant Commissioner for Patents Washington, D.C. 20231

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

This letter is in response to the "Notice to Comply" mailed on March 29, 2001 which indicated that the copy of the "Sequence Listing" in computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823. A copy of "The Notice to Comply" is enclosed.

Enclosed please find a substitute computer readable form (CFR) copy of the "Sequence Listing", a substitute paper copy of the "Sequence Listing", and a statement that the content of the paper and computer readable copies are the same, and where applicable, include no new matter.

Although there should be no fees associated with this Response the Comings or ECH CENTERCIFICOT TECH CENTERCIFICOT And Overpayment, to Deposit Account 16-1852.


Respectfully submitted,

to Mr. B.

Karen Moon Bruce Agent for Applicant(s) Registration No. 42,366

PIONEER HI-BRED INTERNATIONAL, INC. Corporate Intellectual Property 7100 N.W. 62nd Avenue P.O. Box 1000 Johnston, Iowa 50131-1000

Phone: (515) 248-4879 Facsimile: (515) 334-6883



RECEIVED

APR 2 4 2001

UNITED EATER PATENT AND TRADEMARK OFFICE

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/771,045

01/26/2001

Jonathan P. Duvick

1134C

CONFIRMATION NO. 7253

FORMALITIES LETTER

OC0000005917489

Pioneer Hi-Bred International, Inc. Corporate Intellectual Property 7100 N.W. 62nd Avenue P.O. Box 1000 Johnston, IA 50131-1000

Date Mailed: 03/29/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov


A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY

RAW SEQUENCE LISTER



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable

Application Serial Number:

Date Processed by STIC

BEST AVAILABLE COPY

THE ATTACKED PRINTOUT EXPLAINS DETECTED ERRORS

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

MINCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE

APPLICANTAVITHA NOTICE TO COMPLY or,

FOR CRESUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212

FOR SEQUENCE RULES INTERERETATION, PLEAST CONTACT ROBERT WAX, 703-308-4216 PATRICIAL mathen: patin21help@uspto.gov or phone 703-306-4119 (R. Wax) DAVENTERS 30 amai(help: spatin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSIONS:0 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE SEE BELOW

Checker Version 3.0

The Checker Version of Graphication is a state-of the art Windows based software program employing a logic Hand munity discrementaries to check whether a sequence distinguism. compliance with maintainthomical fulls. Chorder Versions of Kvorder Occopions distingues gandenical or the original varion or \$2000 Och tules), and the covera carrien (new rules) excent confirm 1, 1993 as vellens. World intellegand Property Organization (WIPO) Stanford St. 18.

Checken Vectors to a places the previous 1100 detect veryion of Checker and is 728 goinglaint. Checker alter a public used to the k sequence lightings in Conglige Rentable form (CRE) helder subditions their to the United States Patient and Vendenback Office (USPTO). tive of the less to the return the requester having is suggested to result in those chaped require

Checker Argum 24 can be down loaded from his COFTO website of the following address: www ushing the webselfficus immediached



OIPE

DATE: 02/08/2001 SEQUENCE LISTING TIME: 12:14:08 PATENT APPLICATION: US/09/771,045

Input Set : A:\1134CSEQLIST.TXT

Output Set: N:\CRF3\02082001\I771045.raw

Does Not Comply Corrected Diskette Needec. 4 <110> APPLICANT: Duvick, Jonathan P. Gilliam, Jacob T. Maddox, Joyce R. 8 <120> TITLE OF INVENTION: Amino Polyol Amine Oxidase Polynucleotides and Related Polypeptides and Methods of Use 12 <130> FILE REFERENCE: 1134C C--> 14 <140> CURRENT APPLICATION NUMBER: US/09/771,045 C--> 14 <141> CURRENT FILING DATE: 2001-01-26 14 <150> PRIOR APPLICATION NUMBER: US 60/092,936 15 <151> PRIOR FILING DATE: 1998-07-15 17 <150> PRIOR APPLICATION NUMBER: US 60/135,391 18 <151> PRIOR FILING DATE: 1999-05-21 20 <150> PRIOR APPLICATION NUMBER: US 09/352,159 21 <151> PRIOR FILING DATE: 1999-07-12 23 <156> PRIOR APPLICATION NUMBER: US 09/352,168 24 <151> PRIOR FILING DATE: 1999-07-12 26 <160> NUMBER OF SEQ ID NOS: 53 28 <170> SOFTWARE: FastSEQ for Windows Version 3.0 30 <210> SEQ ID NO: 1 31 <211> LENGTH: 372 32 <212> TYPE: DNA 33 <213> ORGANISM: Exophiala spinifera 35 <220> FEATURE: 36 <221> NAME/KEY: misc_feature 37 <222> LOCATION: (346)...(346) 38 <223> OTHER INFORMATION: n = A,T,C or G 40 <400> SEQUENCE: 1 41 gggccccggc gttctcgtag gctgcgcgga gttggtccca gacagacttt tgtcgtacct 120 gettqqactq ttqqqaccac ttccqtcccq qqtctccqac catgaaacag gtaatqqacc 43 attgtcgatc gacgtcgatg ctggtatctc tggcaaatga gatggggtca cagctcgatt 180 44 ggaggaegee egagaageet tgttegegee accaeggett gteecataeg aagaetatet 240 45 tgctatagta gcccaggata gaattttccg ccaatgcttg ettetcggcg ggaagaggtg 300 wt 46 gtgaaaatgt caaggtggga tacaaggttg tcggtaacga aaccancacc tttttgcttc 360 47 ggaacacggc gc 372 49 <210> SEQ ID NO: 2 50 <211> LENGTH: 182 51 <212> TYPE: DNA 52 <213> ORGANISM: Exophiala spinifera 54 <400> SEQUENCE: 2 55 gaattttccg ccaatgcttg cttctcggcg ggaagaggtg gtgaaaatgt caaggtggga 60 56 tacaaggttg teggtaaega aaceaeeace tttttgette ggaacaegge geeegaggee 120 57 gategtaetg tacageegga tgeegaetge teaattteag egaegggggt gttgaggtge 180 58 ac 182 60 <210> SEQ ID NO: 3

61 <211> LENGTH: 29 62 <212> TYPE: DNA

63 <213> ORGANISM: Artificial Sequence

RAW SEQUENCE LISTING DATE: 02/08/2001 TIME: 12:14:08 PATENT APPLICATION: US/09/771,045

Input Set : A:\1134CSEQLIST.TXT
Output Set: N:\CRF3\02082001\I771045.raw

65 <220> FEATURE: 66 <223> OTHER INFORMATION: Designed oligonucleotide for 3' RACE, N21965	
69 <400> SEQUENCE: 3	29
70 tggtttcgtt accgacaacc ttgtatccc	23
72 <210> SEQ ID NO: 4	
73 <211> LENGTH: 28	
74 <212> TYPE: DNA	
75 <213> ORGANISM: Artificial Sequence	
77 <220> FEATURE: 78 <223> OTHER INFORMATION: Designed oligonucleotide for 5' RACE, 21968	
80 <400> SEQUENCE: 4 81 gagttggtcc cagacagact tttgtcgt	28
81 gagttggtcc cagacagact trigicgt 83 <210> SEQ ID NO: 5	
83 <210> SEQ 1D NO. 3 84 <211> LENGTH: 1389	
85 <212> TYPE: DNA	
86 <213> ORGANISM: Exophiala spinifera	
88 <220> FEATURE:	
89 <221> NAME/KEY: CDS	
90 <222> LOCATION: (1)(1386)	
92 <400> SEQUENCE: 5	
93 gac aac gtt geg gac gtg gta gtg gtg ggc gct ggc ttg age ggt ttg	48
94 Asp Asn Val Ala Asp Val Val Val Gly Ala Gly Leu Ser Gly Leu	
95 1 5 10	
97 gag acq gca cgc aaa gto cag gcc gcc ggt ctg too tgc ctc gtt ctt	96
98 Glu Thr Ala Arg Lys Val Gln Ala Ala Gly Leu Ser Cys Leu Val Leu	
99 20 25 30	
TOT dad ded and dan ede dea dag aga dag acc cog ago you can be you	144
102 Glu Ala Met Asp Arg Val Gly Gly Lys Thr Leu Ser Val Gin Ser Gly	
103 35 40 45	
10) CCC qqc aqq acq acc acc acc gao cco ggo gog gog agg acc	192
106 Pro Gly Arg Thr Thr Ile Asn Asp Leu Gly Ala Ala Trp Ile Asn Asp	
107 50 55 60	~
109 age dae cad age gad ged less agri esg see gad age en	240
110 Ser Asn Gln Ser Glu Val Ser Arg Leu Phe Glu Arg Phe His Leu Glu	
111 65 70 75 80	200
113 due dad ete cad add ace de dae cod ace en ser ser ser ser ser	288
114 Gly Glu Leu Gln Arg Thr Thr Gly Asn Ser Ile His Gln Ala Gln Asp	
90 95	336
11/ ddf. aca acc acc aca dct. ccc cac ggs gas cos cos cos cos cos	330
118 Gly Thr Thr Thr Ala Pro Tyr Gly Asp Ser Leu Leu Ser Glu Glu	
119 100 105 110	384
121 gtt gca agt gca ctt gcg gaa ctc ctc ccc gta tgg tct cag ctg atc	20.4
122 Val Ala Ser Ala Leu Ala Glu Leu Leu Pro Val Trp Ser Gln Leu Ile	
123	432
125 gad gag cat age cel cad gat cee day 355 and all land land	
140	
	480
130 Leu Asp Ser Val Ser Phe Ala His Tyr Cys Glu Lys Glu Leu Ash Leu	

RAW SEQUENCE LISTING DATE: 02/08/2001 PATENT APPLICATION: US/09/771,045 TIME: 12:14:08

Input Set : A:\1134CSEQLIST.TXT
Output Set: N:\CRF3\02082001\1771045.raw

							•	•			-						
131	145					150					155					160	
133	cct	gct	gtt	ctc	ggc	gta	gca	aac	cag	atc	aca	cgc	gct	ctg	ctc	ggt	528
134	Pro	Ala	Val	Leu	Gly	Val	Ala	Asn	Gln	Ile	Thr	Arg	Ala	Leu	Leu	Gly	
135					165					170					175		
137	gtg	qaa	gcc	caç	gag	atc	agc	atg	ctt	ttt	ct.c	acc	gac	tac	atc	aag	576
138	Val	Ğlu	Åla	His	Glu	Ile	Ser	Met	Leu	Phe	Leu	Thr	Asp	Tyr	Ile	Lys	•
139				180					185					190			
141	agt.	gcc	acc	ggt	ctc	agt	aat	att	ttc	tcg	gac	aag	aaa	gac	ggc	ggg	624
142	Ser	Ála	Thr	Gly	Leu	Ser	Asn	Ile	Phe	Ser	Asp	Lys	Lys	Asp	Gly	Gly	
143			195					200					205				
145	cag	tat	atg	cga	tgc	aaa	aca	ggt	atg	cag	teg	att	tgc	cat	gcc	atg	672
145	Gln	Tyr	Met	Arg	Cys	Lys	Thr	Gly	Met	Gln	Ser	Ile	Cys	His	Ala	Met	
147		210					215					220					
149	tca	aag	gaa	ctt	gtt	cca	ggc	tca	gtg	cac	ctc	aac	acc	CCC	gtc	gct	720
150	Ser	Lys	Glu	Leu	Val	Pro	Gly	Ser	Val	His	Leu	Asn	Thr	Pro	Val	Ala	
151	225					230					235					240	
153	gaa	att	gag	cag	tcg	gca	tcc	ggc	tgt	aca	gta	cga	tcg	gcc	tcg	ggc	768
154	Glu	Ile	Glu	Gln	Ser	Ala	Ser	Gly	Cys	Thr	Val	Arg	Ser	Ala	Ser	Gly	
155					245					250					255	,	
157	gcc	gtg	ttc	cga	agc	aaa	aag	gtg	gtg	gtt	tcg	tta	ccg	aca	acc	ttg	816
158	Ala	Val	Phe	Arg	Ser	Lys	Lys	Val	Val	Val	Ser	Leu	Pro	Thr	Thr	Leu	
.159				260					265					270			
161	tat	ccc	acc	ttg	aca	ttt	tca	cca	cct	ctt:	CCC	gcc	gag	aag	caa	gca	864
162	Tyr	Pro	Thr	Leu	Thr	P'ie	Ser		Pro	L⇒u	Pro	Ala	Glu	Lys	Gln	Ala	
163			275					280					285				010
165	ttg	gcg	gaa	aat	tct	atc	ctg	gac	tac	tāt	ago	aag	ata	gtc	ttc	gta	912
166	Leu	Ala	Glu	Asn	Ser	Ile		Gly	Tyr	Tyr	Ser		Ile	Val	Phe	Val	
167		290					295					300					0.00
169	tgg	gac	aag	ccg	t.gg	tid	cgc	gaa	caa	ggc	ttc	t.cg	ggc	gtc	ctc	caa	960
170	Trp	Asp	Lys	Fro	Trp		Arg	GLu	Gln	Gly		Ser	GIV	vai	ьeu	GIU	
171	305					310					315					320	1000
173	tcg	agc	tgt	gac	ccc	atc	tca	ttt	gcc	aga	gat	acc	agc	atc	gac	gtc	1008
174	Ser	Ser	Cys	Asp		Ile	Ser	Phe	Ala		Asp	Thr	Ser	ile		Val	
175					325					330					335		1056
177	gat	cga	caa	tgg	tcc	att	acc	tgt	ttc	atg	gtc	gga	gac	ccg	gga	250	1036
178	Asp	Arg	Gln		Ser	119	Thr	Cys	Phe	мет	vaı	Giy	ASD		GIĀ	Arg	
179				340					345				++	350	+~~	~~	1104
181	aag	tgg	tcc	caa	cag	tcc	aag	cag	gta	cga	Caa	aay	Con	y (C	Lyy	yac	1104
182	Lys	Trp		GIn	GIn	Ser	ьys		Val	Arg	GTII	цуs	365	vai	тър	ASP	
183			355				~	360	~~~	~~~	aac			cca	a a a	cca	1152
185	caa	CTC	cgc	gca	gcc	tac	gag	dac	gcc Ala	21.	η (CC	Cln	Val	Dro	Clu	Pro	1132
186	GIn		arg	Ala	Ala	туг	375	ASII	Ald	GT Å	HIG	380	vai	FIO	GIU	110	
187		370			~~~	2+0		+ ~~	+ 00	220	Car		tat	ttc	caa	aga	1200
189	gcc	aac	gtg	CCC	gad	TIC	clu	Trr	tcg Ser	Tare	Gla	Cln	TVY	Phe	Glo	Glv	
190		ASN	val	ьец	GIU	390	<u>G</u> L U	111	Set	פיניי	395	J = 11	-2-	2 110	2711	400	
191	385	aa.~	3.00	acc	ata		aaa	ctc	aac	gat		atc	aca	cta	aat		1248
193	yuu xin	Dro	ayc	ycc λ1 »	Val	Tur	399	Len	Asn	Asn	Leu	Tle	Thr	Leu	Glv	Ser	
194 195	нта	510	Set	мта	405	1 1 L	O T Y	u		410	-40 u	110			415		
Tan					400												

RAW SEQUENCE LISTING DATE: 02/08/2001 PATENT APPLICATION: US/09/771,045 TIME: 12:14:08

Input Set : A:\1134CSEQLIST.TXT
Output Set: N:\CRF3\02082001\1771045.raw

197	gcg	ctc	aga	acg	ccg	ttc	aag	agt	gtt	cat	ttc	gtt	gga	acg	gag	acg		1296
198	Ala	Leu	Arg	Thr	Pro	Phe	Lys	Ser	Val	His	Phe	Val	Gly	Thr	Glu	Thr		
199				420					425					430				
201	tct	tta	gtt	tgg	aaa	ggg	tat	atg	gaa	ggg	gcc	ata	cga	tcg	ggt	caa		1344
202	Ser	Leu	Val	Trp	Lys	Gly	Tyr	Met	Glu	Gly	Ala	Ile	Arg	Ser	Gly	Gln		
203			435					440					445				٠.	
205	cga	ggt	gct	gca	gaa	gtt	gtg	gct	ago	ctg	gtg	cca	gca	gca				1386
206	Arg	Gly	Ala	Ala	Glu	Val	Val	Ala	Ser	Leu	Val	Pro	Ala	Ala				
207	-	450					455					460						
209	taq																	1389
211	<210	> SE	Q ID	NO:	6													
212	<211	> LE	NGTH	: 46	2													
213	<212:	> TY	PE: I	PRT														
214	<2133	> ORG	GANI	5M: 1	Exopl	hiala	a sp	inife	era									
	<400				_		_											
217						Val	Val	Val	Val	Gly	Ala	Gly	Leu	Ser	Gly	Leu		
218	1				5					10		_			15			
219	Glu	Thr	Ala	Arq	Lvs	Val	Gln	Ala	Ala	Gly	Leu	Ser	Cys	Leu	Val	Leu		
220				20					25	-			_	30				
221	Glu	Ala	Met	Asp	Ara	Val	Glv	Glv	Lys	Thr	Leu	Ser	Val	Gln	Ser	Gly		
222	0.0		35		5			40					45			-		
223	Pro	G19		Thr	Thr	Tle	Asn		Leu	Glv	Ala	Ala	Trp	Ile	Asn	Asp		
224	110	50	112 9				55			2		60	•			-		
225	Ser		Gln	Ser	GLu	Va 1		Ara	Leu	Phe	Glu		Ehe	His	Leu	Glu		
226	65	11011	J111	001	0.4	70	-				75	5				80		
227		Glu	Lan	Gln	Δrσ		Thr	Glv	Asn	Ser		His	Gln	Ala	Gln	Asp		
228	Giy	GLU	цец	3111	85	1111		017		90	2. 2. 4.				95			
229	C117	Thr	Thr	Thr		Δla	Pro	Ttr	Gly		Ser	Len	Leu	Ser		Glu		
230	GIÀ	1 111	1111	100	111.0	niu	110	- y -	105	. ID P	00+	100	204	110	014	024		
231	Wa 1	A 1 -	Car		Lau	Λla	c1n	T.411	Leu	Dro	Vai	Фrn	Sur		Len	Tle		
232	vai	Ald	115	Alu	Leu	ALG	Olu	120	_cu		,	++₽	125					
233	Clu	Clu		Car	Lou	Cln	Aen		Lys	Δla	Sar	Pro		Ala	1.98	Ara		
234	Giu	130	ura	261	пец	0111	135	пси	цу		001	140	0111		2,2	9		
235	Lon		Cor	W - 1	cor	Dho		Иic	Tyr	Cve	G111		Glu	Len	Asn	Len		
236	145	ASP	261	Val	361	150	Ald	1113	ı yı	Cys	155	ш ₁ э	02.14	шец	11011	160		
237		7 l n	Val	LOU	C10		Λla	λen	Gln	Tla		Ara	Δla	Len	T.,211			
238	PIO	Ala	vai	цец	165	Val	Alu	ASII	0.11	170	1111	y	niu	шец	175	011		
239	17.0 7	C1	7.7.	ui a		Tlo	cor	Mot	Leu		Lau	Thr	Aen	Tur		Lus		
	Val	GIU	Ата	180	GIU	TTE	ser	Mec	185	FILE	пец	1111	пор	190	110	D		
240	Cam	A 1 -	mh ~		Lou	car	λcn	ria	Phe	Sar	Aen	Tve	Luc		Gla	Glv		
241	ser	Ald		GIY	hea	ser	ASII	200	FILE	261	rsb	1.y	205	АЗР	Gry	Gry		
242	0.1	m	195	3	C	T	m h ss		Mot	Cln	Car	r l o		uic	λla	Mot		
243	GIN		Met	Arg	CAR	гА≳	215	оту	Met	GTH	ಎರಾ	220	CYS	1112	та	ric L		
244	a	210		T	17 a l	Dwa		Con	1/01	u i a	T 011		mhr	Dro	Wal	λla		
245		гÃг	GIU	Leu	val		стλ	ser	Val	HIS		ASII	T 111T.	LTO	vai	240		
246	225	- 1	- 1	0.1	a	230	C	G1	Cure	m b s-	235	7 ~~~	Cor	7 7 ~	Car			
247	Glu	ile	GTI	GIn		АІА	ser	GΤĀ	Cās		val	Arg	ser.	HIG	255	GTĀ		
248					245	7.	.	17- 1	TT - 1	250	C	τ	Dro	m h		Ι		
249	Ala	Val	Phe		ser	гàг	гÃг	val	Val	vai	ser	Leu	5T.O		THE	ьeu		
250				260					265					270				

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/771,045

DATE: 02/08/2001 TIME: 12:14:08

Input Set : A:\1134CSEQLIST.TXT

Output Set: $N:\CRF3\02082001\I771045.raw$

251 252	-	Pro	Thr 275		Thr	Phe	Ser	Pro 280	Pro	Leu	Pro	Ala	Glu 285	Lys	Gln	Ala	
253 254	*	Ala 290	Glu		Ser	Ile	Leu 295		Tyr	Tyr	Ser	Lys		Val	Phe	Val	
255				Pro	Trp		Arg	Glu	Gln	Gly	Phe		Gly	Val	Leu	Gln 320	
256 257	305 Ser	Ser	Cys	Asp		310 Ile	Ser	Phe	Ala		Asp	Thr	Ser	Ile			
258 259	Asp	Arg	Gln		325 Ser	Ile	Thr	Cys		330 Met	Val	Gly	Asp		335 Gly	Arg	
260	_	_	~	340	- 1	_	_	~1	345	_	0.3			350	m		
261 262	Lys	Trp	355	GIn	GIn	Ser	гăг	360	vaı	Arg	Gln	гÀЗ	365	vai	Trp	Asp	
263	C1n	LOU		712	λla	Tur	Clu		λ 1.5	G1+r	Ala	Gln		Pro	Glu	Pro	
264	GIII	370	ALG	нта	AIG	ıyı	375	ASII	нта	GIY	HIA	380	val	F10	GIU	FIO	
265	Ala		Va l	Leu	Glu	Tle		Trp	Ser	Lvs	Gln		Tvr	Phe	Gln	Glv	
266	385			204	024	390				-10	395		- 1			400	
267	Ala	Pro	Ser	Ala	Val	Tyr	Gly	Leu	Asn	Asp	Leu	Ile	Thr	Leu	Gly	Ser	
268					405	-	•			410					415		
269	Ala	Leu	Arg	Thr	Pro	Phe	Lys	Ser	Val	His	Phe	Val	Gly	Thr	Glu	Thr	
270				420					425					430			
271	Ser	Leu		Trp	Lys	Gly	\mathtt{Tyr}	Met	Glu	${\tt Gly}$	Ala	Ile	-	Ser	Gly	Gln	
272			435					440					445				
273	Arg	-	Ala	Ala	Glu	Vai		Ala	Ser	Leu	Vāl		Ala	Ala			
274		450			_		455					460					
276	<210>		i ID	NQ:	/												
~ ~ ~			7/3/00/77	3 4 4													
	<211>				12												
278	<212>	TY	PE: I	ANC			ani	inifo	· * 3								
278 279	<212><213>	YYI ORO	PE: [GANIS	ONA SM: E		niala	spi	inife	era								
278 279 281	<212><213><220>	ORG	PE: I GANIS ATURE	ONA SM: E E:	Exopl	niala	spi	inif∈	era								
278 279 281 282	<212><213><220><221>	ORG FEA	PE: I GANIS ATURE ME/KE	ONA SM: E S: EY: C	Exop! CDS		-	inif∈	era								
278 279 281 282 283	<212><213><220><221><221><222>	TYPORCE FEF NAME LOC	PE: I GANIS ATURE KE/KE LATIO	ONA SM: E S: EY: C ON: (Exoph CDS	. (64	-	inife	era								
278 279 281 282 283 285	<212><213><223><220><221><222><222><221><	TYPORCE ORCE FEA NAME LOCE NAME NAME	PE: I GANIS ATURE ME/KE ME/KE	ONA SM: E S: EY: C ON: (Exop! CDS (1)	(64 on	.6)		era								
278 279 281 282 283 285 286	<212><213><220><221><221><222>	TYPORCE FEA NAM LOC NAM LOC NAM	PE: I GANIS ATURE KE/KE IATIO ME/KE CATIO	ONA SM: E S: EY: C ON: (EY: i	Exoph CDS (1) Intro (647)	(64 on	.6)		era								
278 279 281 282 283 285 286 288	<212><213><221><220><221><222><221><222><222><	TYPE ORG FEA NAM LOC NAM LOC NAM LOC NAM	PE: I GANIS ATURE ME/KE ME/KE CATIO ME/KE	ONA 5M: E 5: EY: C ON: (EY: I ON: (EY: C	Exoph CDS (1) (647) CDS	(64 on ((6) (699)		era			·					
278 279 281 282 283 285 286 298 289	<212><213><220><221><221><222><221><222><221><222><221>	TYH ORC FEA NAM LOC NAM LOC NAM LOC NAM	PE: I GANIS ATURE ME/KE CATIO ME/KE CATIO ME/KE	DNA E: E: ON: (ON: (CY: O ON: (Exoph DS (1) ntro (647) DS (700)	(64 on ((6) (699)		era								
278 279 281 282 283 285 286 298 289	<212><213><220><221><222><221><222><221><222><400>	TYPE ORC FEA NAM LOC NAM LOC NAM LOC NAM LOC SEC	PE: I GANIS ATURE ME/KE CATIO ME/KE CATIO QUENO	ONA E: EY: C ON: (EY: f ON: (ON: (CE: 7	Exoph CDS (1) Intro (647) CDS (700)	(64 on ((699) (1439	9)		ggc	gct	ggc	ttg	agc	ggt	ttg	48
278 279 281 282 283 285 286 288 289 291 292 293	<212><213><220><221><221><221><222><221><222><400> <gac< td=""><td>TYPER OR OF THE PROPERTY OF TH</td><td>PE: I GANIS ATURE ME/KE CATIO ME/KE CATIO QUENO gtt</td><td>ONA SM: E S: ON: (ON: (CY: C ON: (CY: C ON: (CY: C ON: (CY: C ON: (CE: 7</td><td>Exoph (1) (1) (647) (DS (700) (gac Asp</td><td>(64 on (</td><td>(699) (1439) (gta</td><td>)) gtg</td><td>gtg</td><td>Gly</td><td>gct Ala</td><td></td><td></td><td></td><td>Gly</td><td></td><td>48</td></gac<>	TYPER OR OF THE PROPERTY OF TH	PE: I GANIS ATURE ME/KE CATIO ME/KE CATIO QUENO gtt	ONA SM: E S: ON: (ON: (CY: C ON: (CY: C ON: (CY: C ON: (CY: C ON: (CE: 7	Exoph (1) (1) (647) (DS (700) (gac Asp	(64 on ((699) (1439) (gta)) gtg	gtg	Gly	gct Ala				Gly		48
278 279 281 282 283 285 286 298 291 292 293 294	<212><213><220><221><221><221><222><221><222><400> <gac 1<="" asp="" td=""><td>TYI ORC FEA NAM LOC NAM LOC NAM LOC NAM LOC SEC aac</td><td>PE: IGANISATURE ME/KE ME/KE CATIO ME/KE CATIO QUENO gtt Val</td><td>ONA SM: E E: EY: C ON: (CY: C ON: (CY: C ON: (GE: 7 GCG Ala</td><td>Exoph (1) (1) (647) (DS (700) gac Asp</td><td>(64 on ((gtg Val</td><td>(699) (1439) (gta Val</td><td>gtg Val</td><td>gtg Val</td><td>Gly 10</td><td>Ala</td><td>Gly</td><td>Leu</td><td>Ser</td><td>Gly 15</td><td>Leu</td><td></td></gac>	TYI ORC FEA NAM LOC NAM LOC NAM LOC NAM LOC SEC aac	PE: IGANISATURE ME/KE ME/KE CATIO ME/KE CATIO QUENO gtt Val	ONA SM: E E: EY: C ON: (CY: C ON: (CY: C ON: (GE: 7 GCG Ala	Exoph (1) (1) (647) (DS (700) gac Asp	(64 on ((gtg Val	(699) (1439) (gta Val	gtg Val	gtg Val	Gly 10	Ala	Gly	Leu	Ser	Gly 15	Leu	
278 279 281 282 283 285 286 298 291 292 293 294 296	<212><213><220><221><221><222><221><222><420><221><222><1><221><222><100><222><100><222><100><100	TYH ORC FEA NAM LOC NAM LOC NAM LOC NAM LOC AST	PE: IGANISATURE ME/KE ME/KE CATIO ME/KE CATIO QUENO gtt Val	ONA SM: E S: EY: O ON: (EY: û ON: (CY: C ON: (CE: 7 gcg Ala cgc	Exop! ODS (1) otro (647) DS 700) gac Asp 5 aaa	on (64 (gtg Val	(699) (1439) (gta Val	gtg Val	gtg Val gcc	Gly 10 ggt	Ala ctg	Gly tcc	Leu tgc	Ser ctc	Gly 15 gtt	Leu ctt	48
278 279 281 282 283 285 286 298 291 292 293 294 296 297	<212><213><220><221><221><222><221><222><420><221><222><1><221><222><100><222><100><222><100><100	TYH ORC FEA NAM LOC NAM LOC NAM LOC NAM LOC AST	PE: IGANISATURE ME/KE ME/KE CATIO ME/KE CATIO QUENO gtt Val	ONA SM: E S: EY: C ON: (C EY: i ON: (C C EY: C ON: (C C EY: C C C EY:	Exop! ODS (1) otro (647) DS 700) gac Asp 5 aaa	on (64 (gtg Val	(699) (1439) (gta Val	gtg Val	gtg Val gcc Ala	Gly 10 ggt	Ala	Gly tcc	Leu tgc	Ser ctc Leu	Gly 15 gtt	Leu ctt	
278 279 281 282 283 285 286 298 291 292 293 294 296 297 298	<212><213><220><221><221><222><221><222><400> <a gag-gag-gag-gag-gag-gag-gag-gag-gag-gag<="" href="gag-ac-ac-ac-ac-ac-ac-ac-ac-ac-ac-ac-ac-ac-</td><td>TYPE ORC FEA NAM LOC NAM LOC NAM LOC SEC aac Asn acg</td><td>PE: IGANISATURE ME/KE CATIO ME/KE CATIO QUENO gtt Val gca Ala</td><td>DNA SM: E E: EY: C DN: (EY: i DN: (CY: C DN: (CE: 7 gcg Ala cgc Arg 20</td><td>Exoph
(1)
(647)
(DS
(700)
gac
Asp
5
aaa
Lys</td><td>gtg
Val</td><td>(6)
(699)
(1439)
(9ta
Val
Cag
Gln</td><td>gtg
Val
gcc
Ala</td><td>gtg
Val
gcc
Ala
25</td><td>Gly
10
ggt
Gly</td><td>Ala
ctg
Leu</td><td>Gly
tcc
Ser</td><td>Leu
tgc
Cys</td><td>Ser
ctc
Leu
30</td><td>Gly
15
gtt
Val</td><td>Leu
ctt
Leu</td><td>96</td></tr><tr><td>278 279 281 282 283 285 286 288 289 291 292 293 294 296 297 298 300</td><td><212><213><220><221><222><221><222><221><222><400><td>TYI ORC FEA NAM NAM LOC NAM LOC SEC aac Asn acg Thr</td><td>PE: IGANISATURE ME/KE CATIO ME/KE CATIO QUENO gtt Val qca Ala atg.</td><td>DNA SM: E E: EY: C DN: (EY: i DN: (CY: C DN: (CE: 7 gcg Ala cgc Arg 20 gat</td><td>Exophantic (1)</td><td>gtg Val gtc Val</td><td>(6) (699) (1439) (9ta) Val) Cag (Gln)</td><td>gtg Val gcc Ala</td><td>gtg Val gcc Ala 25 åag</td><td>Gly 10 ggt Gly act</td><td>Ala ctg Leu ctg</td><td>Gly tcc Ser</td><td>Leu tgc Cys gta</td><td>Ser ctc Leu 30 caa</td><td>Gly 15 gtt Val tcg</td><td>Leu ctt Leu ggt</td><td></td>	TYI ORC FEA NAM NAM LOC NAM LOC SEC aac Asn acg Thr	PE: IGANISATURE ME/KE CATIO ME/KE CATIO QUENO gtt Val qca Ala atg.	DNA SM: E E: EY: C DN: (EY: i DN: (CY: C DN: (CE: 7 gcg Ala cgc Arg 20 gat	Exophantic (1)	gtg Val gtc Val	(6) (699) (1439) (9ta) Val) Cag (Gln)	gtg Val gcc Ala	gtg Val gcc Ala 25 åag	Gly 10 ggt Gly act	Ala ctg Leu ctg	Gly tcc Ser	Leu tgc Cys gta	Ser ctc Leu 30 caa	Gly 15 gtt Val tcg	Leu ctt Leu ggt	
278 279 281 282 283 285 286 288 291 292 293 294 296 297 298 300 301	<212><213><220><221><222><221><222><221><222><400> <a gag-gag-gag-gag-gag-gag-gag-gag-gag-gag<="" href="gag-gag-gag-gag-gag-gag-gag-gag-gag-gag</td><td>TYI ORC FEA NAM NAM LOC NAM LOC SEC aac Asn acg Thr</td><td>PE: IF GANISATURE ME/KE/KE/KE/KE/KE/KE/KE/KE/KE/KE/KE/KE/KE</td><td>DNA SM: E E: EY: C DN: (EY: i DN: (CY: C DN: (CE: 7 gcg Ala cgc Arg 20 gat</td><td>Exophantic (1)</td><td>gtg
Val
gtc
Val</td><td>(6)
(699)
(1439
(gta
Val
(Cag
(Gln)</td><td>gtg
Val
gcc
Ala
gga
Gly</td><td>gtg
Val
gcc
Ala
25
åag</td><td>Gly
10
ggt
Gly
act</td><td>Ala
ctg
Leu</td><td>Gly
tcc
Ser</td><td>tgc
Cys
gta
Val</td><td>Ser
ctc
Leu
30
caa</td><td>Gly
15
gtt
Val
tcg</td><td>Leu
ctt
Leu
ggt</td><td>96</td></tr><tr><td>278 279 281 282 283 285 286 288 289 291 292 293 294 296 297 298 300 301 302</td><td><212><213><220><221><222><221><222><221><222><400><td>TYMEN TYMEN TYMEN</td><td>PE: IF GANISATURE ME/KE/KE/KE/KE/KE/KE/KE/KE/KE/KE/KE/KE/KE</td><td>ONA SM: E S: EY: O ON: (EY: i ON: (CY: C Ala cgc Arg gat Asp</td><td>CDS (1)ntrc(647) CDS (700) gac Asp 5 aaa Lys cgt</td><td>gtg Val gta Val</td><td>(699) (1439) (14</td><td>gtg Val gcc Ala gga Gly 40</td><td>gtg Val gcc Ala 25 àag Lys</td><td>Gly 10 ggt Gly act Thr</td><td>Ala ctg Leu ctg Leu</td><td>tcc Ser agc Ser</td><td>tgc Cys gta Val 45</td><td>Ser ctc Leu 30 caa Gln</td><td>Gly 15 gtt Val tcg Ser</td><td>Leu ctt Leu ggt Gly</td><td>96 144</td>	TYMEN	PE: IF GANISATURE ME/KE/KE/KE/KE/KE/KE/KE/KE/KE/KE/KE/KE/KE	ONA SM: E S: EY: O ON: (EY: i ON: (CY: C Ala cgc Arg gat Asp	CDS (1)ntrc(647) CDS (700) gac Asp 5 aaa Lys cgt	gtg Val gta Val	(699) (1439) (14	gtg Val gcc Ala gga Gly 40	gtg Val gcc Ala 25 àag Lys	Gly 10 ggt Gly act Thr	Ala ctg Leu ctg Leu	tcc Ser agc Ser	tgc Cys gta Val 45	Ser ctc Leu 30 caa Gln	Gly 15 gtt Val tcg Ser	Leu ctt Leu ggt Gly	96 144
278 279 281 282 283 285 286 288 289 291 292 293 294 296 297 298 300 301 302 304	<212><213><220><221><222><221><222><221><222><400> <a gag-gag-gag-gag-gag-gag-gag-gag-gag-gag<="" href="gag-gag-gag-gag-gag-gag-gag-gag-gag-gag</td><td>TYMEN TYMEN TYMEN</td><td>PE: I
GANIS
ATURE
ME/KE
CATIO
ME/KE
CATIO
QUENO
Val
GCA
Ala
atg
Met
35
agg</td><td>ONA SM: E S: EY: O ON: (EY: i ON: (CY: C Ala cgc Arg gat Asp acg</td><td>CDS (1)ntrc(647) CDS (700) gac Asp 5 aaa Lys cgt Arg act</td><td>gtg
Val
gtc
Val
gta
Val</td><td>(6)
(699)
(1439)
gta
Val
cag
Gln
ggg
Gly
aac</td><td>gtg
Val
gcc
Ala
gga
Gly
40
gac</td><td>gtg
Val
gcc
Ala
25
aag
Lys
ctc</td><td>Gly
10
ggt
Gly
act
Thr</td><td>Ala ctg Leu ctg Leu gct</td><td>tcc
Ser
agc
Ser</td><td>tgc
Cys
gta
Val
45
tgg</td><td>Ser ctc Leu 30 caa Gln atc</td><td>Gly
15
gtt
Val
tcg
Ser</td><td>ctt
Leu
ggt
Gly</td><td>96</td></tr><tr><td>278 279 281 282 283 285 286 288 289 291 292 293 294 296 297 298 300 301 302 304 305</td><td><212><213><220><221><222><221><222><221><222><400><td>TYMEN TYMEN TYMEN</td><td>PE: I GANIS ATURE ME/KE CATIO ME/KE CATIO QUENO Val GCA Ala atg Met 35 agg</td><td>ONA SM: E S: EY: O ON: (EY: i ON: (CY: C Ala cgc Arg gat Asp acg</td><td>CDS (1)ntrc(647) CDS (700) gac Asp 5 aaa Lys cgt Arg act</td><td>gtg Val gtc Val gta Val</td><td>(6) (699) (1439) gta Val cag Gln ggg Gly aac</td><td>gtg Val gcc Ala gga Gly 40 gac</td><td>gtg Val gcc Ala 25 aag Lys ctc</td><td>Gly 10 ggt Gly act Thr</td><td>Ala ctg Leu ctg Leu</td><td>tcc Ser agc Ser</td><td>tgc Cys gta Val 45 tgg</td><td>Ser ctc Leu 30 caa Gln atc</td><td>Gly 15 gtt Val tcg Ser</td><td>ctt Leu ggt Gly</td><td>96 144</td>	TYMEN	PE: I GANIS ATURE ME/KE CATIO ME/KE CATIO QUENO Val GCA Ala atg Met 35 agg	ONA SM: E S: EY: O ON: (EY: i ON: (CY: C Ala cgc Arg gat Asp acg	CDS (1)ntrc(647) CDS (700) gac Asp 5 aaa Lys cgt Arg act	gtg Val gtc Val gta Val	(6) (699) (1439) gta Val cag Gln ggg Gly aac	gtg Val gcc Ala gga Gly 40 gac	gtg Val gcc Ala 25 aag Lys ctc	Gly 10 ggt Gly act Thr	Ala ctg Leu ctg Leu	tcc Ser agc Ser	tgc Cys gta Val 45 tgg	Ser ctc Leu 30 caa Gln atc	Gly 15 gtt Val tcg Ser	ctt Leu ggt Gly	96 144
278 279 281 282 283 285 286 288 289 291 292 293 294 296 297 298 300 301 302 304	<212><213><220><221><222><221><222><221><222><400>																

The types of errors shown exist throughout the Sequence Listing. Please check subsequent sequences for similar errors.

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

VERIFICATION SUMMARY DATE: 02/08/2001 PATENT APPLICATION: US/09/771,045 TIME: 12:14:09

Input Set : A:\1134CSEQLIST.TXT

Output Set: N:\CRF3\02082001\I771045.raw

```
L:14 M:270 C: Current Application Number differs, Replaced Current Application No
L:14 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:46 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
L:349 M:361 W: Invalid Split Codon, Sequence data for SEQ ID#: 7
L:1234 M:258 W: Mandatory Feature missing, <220> FEATURE:
L:1234 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION:
L:1334 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:1335 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:1488 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION:
L:2095 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION:
L:2517 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION:
L:2989 M:258 W: Mandatory Feature missing, <220> FEATURE:
L:2989 M:258 W: Mandatory Feature missing. <223> OTHER INFORMATION:
L:3153 M:259 W: Allowed number of lines exceeded, <223> Other Information:
1:3154 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:3487 M:258 W: Mandatory Feature missing, <220> FEATURE:
L:3487 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION:
L:3810 M:258 W: Mandatory Feature missing, <220> FEATURE:
L:3810 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION:
L:4186 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:39
L:4247 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:40
```



	ERROR DETECTED	SUGGESTED	CORRECTION	SERIAL	NUMBER:C	1911111,045
ATTI				HEADERS, WHICH WERE		Y PTO SOFTWARE
'	_ Wrapped Nucleics			wrapped" down to the next lin		
		-		n a word processor after crea	aung n.	
		Please adjust your	ngnt margin to .3, as	this will prevent "wrapping".		
2	_ Wrapped Aminos			each line "wrapped " down l		
		•	•"	in a word processor after cre	ating it.	
		Please adjust your	right margin to .3, as	this will prevent "wrapping".		
3	Incorrect Line Length	The rules require th	nat a line not exceed 7	2 characters in length. This i	ncludes spaces	
4	Misaligned Amino Acid	The numbering und	der each 5th amino aci	d is misaligned. This may be	caused by the t	use of tabs
	Numbering	between the number	ering. It is recommend	ed to delete any tabs and use	spacing between	en the numbers.
5	Non-ASCII	This file was not sa	ved in ASCII (DOS) te	xt, as required by the Seque	nce Rules.	
		Please ensure your	subsequent submissi	on is saved in ASCII text so t	hat it can be pro	xessed.
6	Variable Length	Sequence(s)	contain n's or Xaa's wi	nich represented more than o	ne residue.	
				epresent a single residue.		
		Please present the	maximum number of e	ach residue having variable l	ength and	•
		indicate in the (ix) f	eature section that so	ne may be missing.		
7	Patentin ver. 2.0 "bug"	A "bug" in Patentin	version 2.0 has cause	d the <220>-<223> section to	o be missing fro	m amino acid
		sequence(s)	Normally, P	atentin would automatically g	enerate this sec	tion from the
		previously coded no	ucleic acid sequence.	Please manually copy the re-	evant <220>-<2	23> section
		to the subsequent a	amino acid sequence.	This applies primarily to t	he mandatory	<220>-<223>
		sections for Artific	ial or Unknown sequ	iences.		
8	Skipped Sequences	Sequence(s)	nissing. If intentional,	please use the following form	at-for each skip	ped sequence:
	(OLD RULES)		FOR SEQ ID NO:X:	· ·		•
	,	• •		o not insert any headings und	fer "SEQUENC	E CHARACTERISTICS")
		(xi) SEQUENCE DE	SCRIPTION:SEQ ID	NO:X:		
	·	This sequence is in	ntentionally skipped			
		Please also adjust th	ne "(iii) NUMBER OF :	, SEOUENCES:* response to	include the skipp	ped sequence(s).
9	Skipped Sequences	Sequence(s) п	nissing. If intentional, p	elease use the following form	at for each skipp	ped sequence.
	(NEW RULES)	<210> sequence id	f number	•		
		<400> sequence io	i number			
		000				
10	Use of n's or Xaa's	Use of n's and/or Xa	a's have been detecte	d in the Sequence Listing.		
	(NEW RULES)	Use of <220> to <22	3> is MANDATORY i	n's or Xaa's are present.		
		In <220> to <223> s	ection, please explain	ocation of n or Xaa, and wh	ich residue n or	Xaa represents.
11	Use of <213>Organism			ndatory field or its responsé.		
1	(NEW RULES)	10.	and more	•	-	
12 1	Use of <220>Feature	Sequence(s) / 7	re missing the <220×F	eature and associated headi	nas ·	
			-	<213>ORGAŅISM is "Artific	_	m"
				al in <220> to <223> sectio		····
•	•	•	_	Vol. 63, No. 104, pp.		(Sec. 1.823 of new Rules
12	Detection of Company	Dinggo do - et use "	Copy to District	in a of Oatontla version 2.5	This serves -	corrupted
13				on of Patentin version 2.0. identifiers and responses (a		

Instead, please use "File Manager" or any other means to copy file to floppy disk.

file, Tesalting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing).